FITC anti-mouse IFN-γ Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

E. coli-expressed, recombinant mouse IFN-γ

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.

Concentration

0.5 mg/ml

Storage & Handling

The IFN-γ antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

ICFC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per 10⁶ cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser

Blue Laser (488 nm)

Application Notes

ELISA^1-4,11,14 or ELISPOT⁵ Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry^7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations.
Neutralization^1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections^6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)

1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
7. Ferrick D, et al. 1995. Nature 373:255. (FC)
8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)

Product Citations

1. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
2. Laura C Burzynski et al. 2019. Immunity. 50(4):1033-1042 . PubMed
3. Wang X, et al. 2019. Cell Res. 29:787. PubMed
4. Chuang H, et al. 2014. Nat Commun. 5:4602. PubMed
5. Li B, Schmidt N 2016. PLoS One. 11: 0162427. PubMed
6. Chen N, et al. 2021. Front Immunol. 12:756423. PubMed
7. Yamazaki S, et al. 2022. Mucosal Immunol. :. PubMed
8. Schenkel JM, et al. 2021. Immunity. 54:2338. PubMed
9. D'Angeli V, et al. 2022. Eur J Immunol. 52:1058. PubMed
10. Wang H, et al. 2022. Immunol Cell Biol. 100:547. PubMed
11. Zhao Z, et al. 2022. Adv Sci (Weinh). 9:e2201293. PubMed
12. Lin G, et al. 2022. Int J Immunopathol Pharmacol. 36:3946320221117933. PubMed
13. Balood M, et al. 2022. Nature. 611:405. PubMed
14. Xu H, et al. 2022. Aging Dis. 13:1875. PubMed
15. Wang R, et al. 2023. iScience. 26:105954. PubMed
16. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
17. Belk JA, et al. 2022. Cancer Cell. 40:768. PubMed
18. Zhao L, et al. 2022. Oncogene. 41:4200. PubMed
19. Konjar S, et al. 2022. Proc Natl Acad Sci U S A. 119:e2202144119. PubMed
20. Sanmarco LM, et al. 2022. Nature. 611:801. PubMed
21. Deák P, et al. 2022. Cell Rep. 41:111563. PubMed
22. Zhao Q, et al. 2023. Signal Transduct Target Ther. 8:40. PubMed
23. Li G, et al. 2023. Cell Death Dis. 14:185. PubMed
24. Fan NW, et al. 2023. FASEB J. 37:e22855. PubMed
25. Tang C, et al. 2023. Nat Commun. 14:1493. PubMed
26. Ye S, et al. 2023. Front Oncol. 13:1202750. PubMed
27. Yu Y, et al. 2022. iScience. 25:105004. PubMed
28. Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed
29. Ford K, et al. 2020. Cancer Res. 80:1846. PubMed
30. Kim EH, et al. 2020. Elife. 9:00. PubMed
31. Zhu C, et al. 2018. Sci Rep. 5.113194444. PubMed
32. Onodera A, et al. 2017. J Immunol. 10.4049/jimmunol.1602129. PubMed
33. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
34. Kenichi Shimada et al. 2018. Immunity. 49(5):873-885 . PubMed
35. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
36. Magen A, et al. 2019. Cell Rep. 29:3019. PubMed
37. Hewitson JP, et al. 2020. J Immunol. 204:2949. PubMed
38. Volpedo G, et al. 2022. NPJ Vaccines. 7:32. PubMed
39. Gao Y, et al. 2020. Nat Cell Biol. 1064:22. PubMed
40. Weigelin B, et al. 2015. Proc Natl Acad Sci U S A. 112:7551. PubMed
41. Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed
42. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
43. Isakova-Sivak I, et al. 2020. Vaccines (Basel). 8:00. PubMed
44. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
45. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
46. Cai B, et al. 2021. Mol Cancer. 20:165. PubMed
47. Sehnert B, et al. 2022. Front Immunol. 13:921488. PubMed
48. Khan IM, et al. 2021. Immunohorizons. 5:703. PubMed
49. Sato Y, et al. 2021. J Clin Invest. Online ahead of print. PubMed
50. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
51. Ontiveros-Padilla L, et al. 2021. Microorganisms. 9:. PubMed
52. Wang Z, et al. 2020. Autophagy. 1:. PubMed
53. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
54. Ni P, et al. 2014. J Immunol . 193:1778. PubMed
55. Larena M, et al. 2011. J Virol. 85:5446. PubMed
56. Chao CC, et al. 2020. Cell. 179(7):1483-1498.e22.. PubMed
57. Lu Y, et al. 2020. Cell. 180(6):1081-1097. PubMed
58. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
59. Sasaki K, et al. 2019. Nat Commun. 10:3878. PubMed
60. Yang X, et al. 2019. Oncotarget. 10:4180. PubMed
61. Alessandrini F, et al. 2019. Oncogene. 38:4467. PubMed
62. Sophie Thiemann et al. 2017. Cell host & microbe. 21(6):682-694 . PubMed
63. He J, et al. 2020. Cell Reports. 29(9):2718-2730.e6.. PubMed
64. Wei F, et al. 2014. Cancer Res. 74:5989. PubMed
65. Montel-Hagen A, et al. 2020. Cell Rep. 33:108320. PubMed
66. Khakhum N, et al. 2021. NPJ Vaccines. 6:72. PubMed
67. Zhao F, et al. 2022. Front Immunol. 13:873720. PubMed
68. Pu Y, et al. 2022. Transl Psychiatry. 12:223. PubMed
69. Ni P, et al. 2014. Mol Immunol. 62:199. PubMed
70. Dar HY, et al. 2018. Sci Rep. 8:2503. PubMed
71. Dar HY, et al. 2018. Bone Rep. 8:46. PubMed
72. Nika L, et al. 2019. Vaccines (Basel). 7. PubMed
73. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
74. Li Y, et al. 2015. J Nutr Biochem. Available online 8 August 2015. PubMed
75. Du Y, et al. 2022. Nat Commun. 13:231. PubMed
76. Zhang L, et al. 2022. Front Immunol. 13:828263. PubMed
77. Pardy RD, et al. 2021. Nat Commun. 12:4051. PubMed
78. Gudgeon N, et al. 2022. Cell Rep. 40:111193. PubMed
79. Crooks SD, et al. 2022. Immunohorizons. 6:705. PubMed
80. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
81. Chung NH, et al. 2022. Vaccine. 40:574. PubMed
82. Baier FA, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:745. PubMed
83. Stutz MD, et al. 2021. Immunity. 54(8):1758-1771.e7. PubMed
84. Tartey S, et al. 2021. Cancer Research. 81(9):2358-2372. PubMed
85. Cheng Y, et al. 2020. PLoS Pathog. 16:e1008569. PubMed
86. Ren W, et al. 2018. Mucosal Immunol. 12:531. PubMed
87. Guo C, et al. 2017. Methods Mol Biol. 1709:345. PubMed
88. Gao X, et al. 2010. Mol Immunol. 47:2397. PubMed
89. Kedzierski L, et al. 2014. PLoS Pathog. 10:1004134. PubMed
90. White C, et al. 2015. J Immunol. 194:697. PubMed
91. Sood S, et al. 2016. J Immunol. 197: 429 - 440. PubMed
92. Deerhake ME, et al. 2021. Immunity. 54(3):484-498.e8. PubMed
93. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
94. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
95. Liu B, et al. 2022. Mol Med Rep. 26:. PubMed
96. Ding P, et al. 2022. Bone Res. 10:42. PubMed
97. Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed
98. Vardhana SA, et al. 2020. Nat Immunol. 1.584722222. PubMed
99. Pinget G, et al. 2016. Immunol Cell Biol. 10.1038/icb.2016.48. PubMed
100. Gagnon JD, et al. 2019. Cell Rep. 28:2169. PubMed
101. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
102. Montfort M, et al. 2004. J Immunol. 173:4084. PubMed
103. Li Y, et al. 2021. Elife. 10:. PubMed
104. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
105. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
106. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
107. Olivo Pimentel V, et al. 2021. J Immunother Cancer. 9:. PubMed
108. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
109. Miyauchi E, et al. 2020. Nature. 585:102. PubMed
110. Wu B, et al. 2021. Immunity. 54(2):308-323.e6. PubMed
111. Lebrun A, et al. 2015. J Immunol. 195: 4358 - 4368. PubMed
112. Nakornpakdee Y, et al. 2018. Asian Pac J Allergy Immunol. 36:265. PubMed
113. Brenndörfer E, et al. 2014. J Immunol. 192:1671. PubMed
114. M H, et al. 2016. Open Bio. 6: 150208. PubMed
115. Fernández-Orth J, et al. 2020. Eur J Immunol. . PubMed
116. Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed
117. Li N, et al. 2022. Nat Commun. 13:7281. PubMed
118. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
119. Harb H, et al. 2020. Nat Immunol. 1359:21. PubMed
120. Yuan C, et al. 2015. Biochem Biophys Res Commun. 464: 249-255. PubMed
121. Lee J, et al. 2007. Nat Immunol. 8:181. PubMed
122. McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed
123. Moufarrij S, et al. 2020. Sci Rep. 10:3470. PubMed
124. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
125. Kong XF, et al. 2018. Nat Immunol. 19:973. PubMed
126. Field CS, et al. 2020. Cell Metab. 31:422. PubMed
127. Zhu E, et al. 2014. J Immunol. 192:5599. PubMed
128. Takahashi T, et al. 2017. J Exp Med. 10.1084/jem.20160247. PubMed
129. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
130. Hao L, et al. 2021. Br J Pharmacol. 178:4726. PubMed
131. Huang LJ, et al. 2021. Immunity. 54(8):1728-1744.e7. PubMed
132. Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed
133. Zeng J, et al. 2020. Int J Biol Sci. 1.939583333. PubMed
134. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
135. Sartorius R, et al. 2018. Front Immunol. 1.413888889. PubMed
136. Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed
137. Zamora-Chimal J, et al. 2017. Immunobiology. 222(2):454-462. PubMed
138. Wang J, et al. 2020. Cell. 183(7):1867-1883.e26. PubMed
139. Aggarwal N, et al. 2021. Cell Rep. 37:110170. PubMed
140. Tseng SH, et al. 2021. J Biomed Sci. 28:63. PubMed
141. Nakazawa S, et al. 2020. Sci Rep. 10:14559. PubMed
142. Ren X, et al. 2021. Cell Death Dis. 12:484. PubMed
143. Dai B, et al. 2021. Cell Reports Medicine. 2(8):100381. PubMed
144. Angelou CC, et al. 2020. Frontiers in Immunology. 2.586805556. PubMed
145. Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed

RRID

AB_315399 (BioLegend Cat. No. 505805)
AB_315399 (BioLegend Cat. No. 505806)

Antigen Details

Structure

Cytokine; dimer; 40-80 kD (Mammalian)

Bioactivity

Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs

Cell Sources

CD8⁺ and CD4⁺ T cells, NK cells

Cell Targets

T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts

Receptors

IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)

Cell Type

Tregs

Biology Area

Cell Biology, Immunology, Neuroinflammation, Neuroscience

Molecular Family

Cytokines/Chemokines

Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation

Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone

Gene ID

15978 View all products for this Gene ID

UniProt

View information about IFN-gamma on UniProt.org

Related Protocols

• Surface and Intracellular Cytokine Staining for Flow Cytometry - Video
• Intracellular Flow Cytometry Staining Protocol

Other Formats